Cizzle Bio Welcomes Dr. William Dalton as Head of Clinical Trials
Cizzle Bio, Inc. is proud to announce that Dr. William (Bill) S. Dalton, a globally recognized leader in oncology and precision medicine, has joined our team as the Head of Clinical Trials. Dr. Dalton brings a wealth of expertise and leadership in cancer research, clinical development, and personalized medicine—positioning Cizzle Bio for groundbreaking advancements in early cancer detection.
A Visionary in Cancer Research and Precision Medicine
Dr. Dalton’s remarkable career spans decades of pioneering work in oncology. He is the Founder of M2Gen (now known as AsterInsights), a biotechnology company dedicated to advancing precision medicine through data-driven cancer research. Prior to this, he served as the President, CEO, and Center Director of the prestigious Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center.
During his leadership at Moffitt, Dr. Dalton was instrumental in developing the Total Cancer Care Protocol, a transformative initiative that collects and utilizes patient clinical and molecular data to improve personalized cancer care. This initiative led to the formation of ORIEN (Oncology Research Information Exchange Network), a collaboration among 18 leading cancer centers dedicated to data sharing and accelerating cancer research. Today, more than 325,000 patients have contributed to this effort, enabling critical advancements in cancer treatment.
Leading Cizzle Bio’s Clinical Trials
At Cizzle Bio, Dr. Dalton will lead the clinical development of our innovative cancer detection technologies, including the CIZ1B Lung Cancer Test and the DEX-G2 Gastric Cancer Test. His extensive experience in clinical trial design, data integration, and precision medicine will play a vital role in bringing these cutting-edge diagnostics to market.
CIZ1B Lung Cancer Test: A non-invasive blood test designed to detect early-stage lung cancer with high sensitivity and specificity, offering a powerful alternative to traditional diagnostic methods.
DEX-G2 Gastric Cancer Test: A groundbreaking dual-biomarker blood test that combines cell-free and exosomal miRNAs to accurately detect gastric cancer in its earliest stages.
Dr. Dalton’s expertise will ensure that our clinical trials meet the highest standards of scientific rigor, accelerating our mission to make early cancer detection accessible and effective.
Driving Innovation Through Leadership
Dr. Dalton’s impressive background includes authoring over 200 publications, holding 12 patents in drug discovery and information networking, and serving on numerous not-for-profit boards. He has also held leadership roles in renowned organizations such as the Personalized Medicine Coalition, the Association of American Cancer Institutes (AACI), and the American Association for the Advancement of Science (AAAS).
His commitment to improving cancer outcomes through innovation and collaboration perfectly aligns with Cizzle Bio’s mission: “Detect Early, Save Lives.”
A Promising Future for Cancer Diagnostics
With Dr. Dalton at the helm of our clinical trials, Cizzle Bio is poised to accelerate the development and launch of transformative cancer diagnostics. His leadership will guide us in expanding our reach, fostering strategic partnerships, and ultimately saving lives through early detection.
Please join us in welcoming Dr. William Dalton to the Cizzle Bio team. We are honored to have his visionary leadership driving our mission forward.
